Literature DB >> 18591234

Type III secretion decreases bacterial and host survival following phagocytosis of Yersinia pseudotuberculosis by macrophages.

Yue Zhang1, James Murtha, Margaret A Roberts, Richard M Siegel, James B Bliska.   

Abstract

Yersinia pseudotuberculosis uses a plasmid (pYV)-encoded type III secretion system (T3SS) to translocate a set of effectors called Yops into infected host cells. YopJ functions to induce apoptosis, and YopT, YopE, and YopH act to antagonize phagocytosis in macrophages. Because Yops do not completely block phagocytosis and Y. pseudotuberculosis can replicate in macrophages, it is important to determine if the T3SS modulates host responses to intracellular bacteria. Isogenic pYV-cured, pYV(+) wild-type, and yop mutant Y. pseudotuberculosis strains were allowed to infect bone marrow-derived murine macrophages at a low multiplicity of infection under conditions in which the survival of extracellular bacteria was prevented. Phagocytosis, the intracellular survival of the bacteria, and the apoptosis of the infected macrophages were analyzed. Forty percent of cell-associated wild-type bacteria were intracellular after a 20-min infection, allowing the study of the macrophage response to internalized pYV(+) Y. pseudotuberculosis. Interestingly, macrophages restricted survival of pYV(+) but not pYV-cured or DeltayopB Y. pseudotuberculosis within phagosomes: only a small fraction of the pYV(+) bacteria internalized replicated by 24 h. In addition, approximately 20% of macrophages infected with wild-type pYV(+) Y. pseudotuberculosis died of apoptosis after 20 h. Analysis of yop mutants expressing catalytically inactive effectors revealed that YopJ was important for apoptosis, while a role for YopE, YopH, and YopT in modulating macrophage responses to intracellular bacteria could not be identified. Apoptosis was reduced in Toll-like receptor 4-deficient macrophages, indicating that cell death required signaling through this receptor. Treatment of macrophages harboring intracellular pYV(+) Y. pseudotuberculosis with chloramphenicol reduced apoptosis, indicating that the de novo bacterial protein synthesis was necessary for cell death. Our finding that the presence of a functional T3SS impacts the survival of both bacterium and host following phagocytosis of Y. pseudotuberculosis suggests new roles for the T3SS in Yersinia pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591234      PMCID: PMC2519449          DOI: 10.1128/IAI.00183-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  A distinctive role for the Yersinia protein kinase: actin binding, kinase activation, and cytoskeleton disruption.

Authors:  S J Juris; A E Rudolph; D Huddler; K Orth; J E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence.

Authors:  D S Black; J B Bliska
Journal:  Mol Microbiol       Date:  2000-08       Impact factor: 3.501

Review 3.  Differentiate to thrive: lessons from the Legionella pneumophila life cycle.

Authors:  Ari B Molofsky; Michele S Swanson
Journal:  Mol Microbiol       Date:  2004-07       Impact factor: 3.501

4.  Salmonella pathogenicity island 1-independent induction of apoptosis in infected macrophages by Salmonella enterica serotype typhimurium.

Authors:  A W van der Velden; S W Lindgren; M J Worley; F Heffron
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Inhibition of phagocytosis in Yersinia pseudotuberculosis: a virulence plasmid-encoded ability involving the Yop2b protein.

Authors:  R Rosqvist; I Bölin; H Wolf-Watz
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

6.  The virulence protein Yop5 of Yersinia pseudotuberculosis is regulated at transcriptional level by plasmid-plB1-encoded trans-acting elements controlled by temperature and calcium.

Authors:  A Forsberg; H Wolf-Watz
Journal:  Mol Microbiol       Date:  1988-01       Impact factor: 3.501

7.  Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis.

Authors:  M Achtman; K Zurth; G Morelli; G Torrea; A Guiyoule; E Carniel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

8.  The response regulator PhoP of Yersinia pseudotuberculosis is important for replication in macrophages and for virulence.

Authors:  Jens P Grabenstein; Michael Marceau; Céline Pujol; Michel Simonet; James B Bliska
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  The plasmid-encoded Yop2b protein of Yersinia pseudotuberculosis is a virulence determinant regulated by calcium and temperature at the level of transcription.

Authors:  I Bölin; H Wolf-Watz
Journal:  Mol Microbiol       Date:  1988-03       Impact factor: 3.501

10.  Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.

Authors:  A Celada; P W Gray; E Rinderknecht; R D Schreiber
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  21 in total

1.  A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; Jr-Shiuan Lin; Stephen T Smiley; James B Bliska
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

2.  The presence of professional phagocytes dictates the number of host cells targeted for Yop translocation during infection.

Authors:  Enrique A Durand; Francisco J Maldonado-Arocho; Cynthia Castillo; Rebecca L Walsh; Joan Mecsas
Journal:  Cell Microbiol       Date:  2010-02-09       Impact factor: 3.715

Review 3.  Modulation of innate immune responses by Yersinia type III secretion system translocators and effectors.

Authors:  James B Bliska; Xiaoying Wang; Gloria I Viboud; Igor E Brodsky
Journal:  Cell Microbiol       Date:  2013-07-29       Impact factor: 3.715

4.  Human and animal isolates of Yersinia enterocolitica show significant serotype-specific colonization and host-specific immune defense properties.

Authors:  Julia Schaake; Malte Kronshage; Frank Uliczka; Manfred Rohde; Tobias Knuuti; Eckhard Strauch; Angelika Fruth; Melissa Wos-Oxley; Petra Dersch
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

5.  YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection.

Authors:  Yue Zhang; James B Bliska
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

6.  Effector CD8+ T cells are generated in response to an immunodominant epitope in type III effector YopE during primary Yersinia pseudotuberculosis infection.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; James B Bliska
Journal:  Infect Immun       Date:  2014-05-05       Impact factor: 3.441

7.  Characterization of Pyrin Dephosphorylation and Inflammasome Activation in Macrophages as Triggered by the Yersinia Effectors YopE and YopT.

Authors:  Natasha P Medici; Maheen Rashid; James B Bliska
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

8.  Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.

Authors:  Betty L Noel; Sarit Lilo; Daniel Capurso; Jim Hill; James B Bliska
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

9.  Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

10.  EseD, a putative T3SS translocon component of Edwardsiella tarda, contributes to virulence in fish and is a candidate for vaccine development.

Authors:  Bo Wang; Zhao Lan Mo; Peng Xiao; Jie Li; Yu Xia Zou; Bin Hao; Gui Yang Li
Journal:  Mar Biotechnol (NY)       Date:  2010-01-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.